Probiotix Health PLC Partner agreement with SymbioPharm

RNS Number : 3304E

Probiotix Health PLC

26 February 2024

 

ProBiotix Health plc

("ProBiotix" or the "Company")

 

Partner agreement with SymbioPharm

 

ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces it has entered into a partnership agreement with SymbioPharm, a German company pioneering in microbiome research and knowledge-based probiotics. SymbioPharm has secured its position as a leading innovator and provider of probiotics, medicinal products and dietary supplements in Germany, Austria and Switzerland where it is considered a top tier consumer brand. SymbioPharm's distribution network spans direct-to-consumer channels as well as a comprehensive online and offline pharmacy presence.

 

The agreement allows SymbioPharm to utilise ProBiotix's CholBiome® CH formulation to target and reduce cholesterol in their branded consumer products. SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions. The agreement covers sales in Germany, Austria and Switzerland, focusing on maximising market penetration through strategic pharmacy partnerships.

 

The unique and innovative formulation developed by ProBiotix comes with a European Food Safety Authority (EFSA) health claim, specific for cholesterol.

 

Steen Andersen, CEO of ProBiotix Health plc commented: "We are delighted that Symbiopharm, a recognised leader in the probiotic space, has engaged with ProBiotix Health. This collaboration is strategically aligned with our goal of extending the reach of our unique finished product formulations within the DACH region (Germany, Austria and Switzerland). This is an important step for us to further expand our business in the consumer health segment, and allow us to reach a broader audience, enhancing market presence and influence."

 

Tobias Brodtkorb, CEO of SymbioPharm added: "We are very pleased to have entered into this agreement with ProBiotix Health. We are a collaborative business and are passionate about natural treatments using live bacteria. Our focus is not only on effective therapies, but also on the associated diagnostics and scientific research on the microbiome, and we find our model fits in naturally with ProBiotix and their mission. We are delighted to be working closely with them and hope for a strong relationship going forward."

 

For further information, please contact:

 

ProBiotix Health plc	https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive	Contact via Walbrook below
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker)	Tel: [phone]
Mark Anwyl
Duncan Vasey
Walbrook PR Ltd	[e-mail]
Anna Dunphy	Mob: [phone]

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXFLFVEFDIVFIS